High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation
详细信息 查看全文
- 作者：Tatiana V. Gorodnovaa ; 1 ; Anna P. Sokolenkob ; c ; 1 ; Alexandr O. Ivantsovc ; d ; Aglaya G. Iyevlevab ; c ; Evgeny N. Suspitsinb ; c ; Svetlana N. Aleksakhinab ; Grigory A. Yanusb ; c ; Alexandr V. Togob ; c ; Sergey Ya. Maximova ; Evgeny N. Imyanitovb ; c ; e ; f ; evgeny@imyanitov.spb.ru" class="auth_mail" title="E-mail the corresponding author
- 关键词：BRCA1 ; Ovarian cancer ; Neoadjuvant therapy ; Loss of heterozygosity (LOH)
- 刊名：Cancer Letters
- 出版年：2015
- 出版时间：28 December 2015
- 年：2015
- 卷：369
- 期：2
- 页码：363-367
- 全文大小：1436 K
文摘
- •
Ovarian carcinomas arising in BRCA1/2 germ-line mutation carriers show high sensitivity to platinum-based neoadjuvant therapy.
- •
Chemonaive hereditary ovarian cancers frequently demonstrate somatic loss of the wild-type BRCA1 allele.
- •
Platinum therapy results in a rapid selection of tumor cell clones with restored heterozygous BRCA1 status.